iStent inject and cataract surgery for mild-to-moderate primary open angle glaucoma in Japan: a cost-utility analysis
Author:
Corresponding Author:

Ataru Igarashi. Yokohama City University School of Medicine, Unit of Public Health and Preventive Medicine, 3-9 Fukuura, Kanazawa Ward, Yokohama 236-0027, Japan. atarui1@mac.com

  • Article
  • | |
  • Metrics
  • |
  • Reference [1]
  • |
  • Related
  • | | |
  • Comments
    Abstract:

    AIM: To evaluate the cost-utility of iStent inject® with cataract surgery vs cataract surgery alone in patients with mild-to-moderate primary open angle glaucoma (POAG) in the Japanese setting from a public payer's perspective. METHODS: A Markov model was adapted to estimate the cost-utility of iStent inject® plus cataract surgery vs cataract surgery alone in one eye in patients with mild-to-moderate POAG over lifetime horizon from the perspective of Japanese public payer. Japanese sources were used for patients' characteristics, clinical data, utility, and costs whenever available. Non-Japanese data were validated by Japanese clinical experts. RESULTS: In the probabilistic base case analysis, iStent inject® with cataract surgery was found to be cost-effective compared with cataract surgery alone over a lifetime horizon when using the ¥5 000 000/quality-adjusted life year (QALY) willingness-to-pay threshold. The incremental cost-utility ratio (ICUR) was estimated to be ¥1 430 647/QALY gained and the incremental cost-utility ratio (ICER) was estimated to be ¥12 845 154/blind eye avoided. iStent inject® with cataract surgery vs cataract surgery alone was found to increase costs (¥1 025 785 vs ¥933 759, respectively) but was more effective in increasing QALYs (12.80 vs 12.74) and avoiding blinded eyes (0.133 vs 0.141). The differences in costs were mainly driven by costs of primary surgery (¥279 903 vs ¥121 349). In the scenario analysis from a societal perspective, which included caregiver burden, iStent inject® with cataract surgery was found to dominate cataract surgery alone. CONCLUSION: The iStent inject® with cataract surgery is a cost-effective strategy over cataract surgery alone from the public payer's perspective and cost-saving from the societal perspective in patients with mild-to-moderate POAG in Japan.

    Reference
    1 Yamada M, Hiratsuka Y, Roberts CB, Pezzullo ML, Yates K, Takano S, Miyake K, Taylor HR. Prevalence of visual impairment in the adult Japanese population by cause and severity and future projections. Ophthalmic Epidemiol 2010;17(1):50-57.<br>2 Morizane Y, Morimoto N, Fujiwara A, Kawasaki R, Yamashita H, Ogura Y, Shiraga F. Incidence and causes of visual impairment in Japan: the first nation-wide complete enumeration survey of newly certified visually impaired individuals. Jpn J Ophthalmol 2019;63(1):26-33.<br>3 Iwase A, Suzuki Y, Araie M, Yamamoto T, Abe H, Shirato S, Kuwayama Y, Mishima HK, Shimizu H, Tomita G, Inoue Y, Kitazawa Y, Tajimi Study Group JGS. The prevalence of primary open-angle glaucoma in Japanese: the Tajimi Study. Ophthalmology 2004;111(9):1641-1648.<br>4 Tham YC, Li X, Wong TY, Quigley HA, Aung T, Cheng CY. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology 2014;121(11):2081-2090.<br>5 Yamamoto T, Iwase A, Araie M, Suzuki Y, Abe H, Shirato S, Kuwayama Y, Mishima HK, Shimizu H, Tomita G, Inoue Y, Kitazawa Y, Tajimi Study Group JGS. The Tajimi Study report 2: prevalence of primary angle closure and secondary glaucoma in a Japanese population. Ophthalmology 2005;112(10):1661-1669.<br>6 Quigley HA. Glaucoma. Lancet 2011;377(9774):1367-1377.<br>7 SPECIAL ISSUE : The Japan Glaucoma Society Guidelines for Glaucoma (4th Edition). Nippon Ganka Gakkai Zasshi 2018;122(1):5-53.<br>8 Chang CP, Hodapp EA. Risk Factors in glaucomatous progression, 2015. https://glaucomatoday.com/articles/2015-sept-oct/risk-factors-in-glaucomatous-progression<br>9 Canadian Ophthalmological Society Glaucoma Clinical Practice Guideline Expert Committee, Canadian Ophthalmological Society. Canadian Ophthalmological Society evidence-based clinical practice guidelines for the management of glaucoma in the adult eye. Can J Ophthalmol 2009;44(Suppl 1):S7-S93.<br>10 Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M, Group EMGT. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol 2002;120(10):1268-1279.<br>11 Vizzeri G, Weinreb RN. Cataract surgery and glaucoma. Curr Opin Ophthalmol 2010;21(1):20-24.<br>12 Nelson P, Aspinall P, Papasouliotis O, Worton B, O'Brien C. Quality of life in glaucoma and its relationship with visual function. J Glaucoma 2003;12(2):139-150.<br>13 Kashiwagi K, Furuya T. Persistence with topical glaucoma therapy among newly diagnosed Japanese patients. Jpn J Ophthalmol 2014;58(1):68-74.<br>14 Kashiwagi K, Chono E, Koesters S, Yap PS. Persistence and treatment patterns of fixed combination drugs for glaucoma: a retrospective claims database study in Japan. BMC Ophthalmol 2020;20(1):223.<br>15 Corporation G. Glaukos Corporation 2017 Investor Day. 2017.<br>16 Intraocular Drainage for Cataract Surgery Conference. Requirements for the Use of Intraocular Drains in Cataract Surgery (2nd Edition). Nippon Ganka Gakkai Zasshi 2016;120(7):494-497.<br>17 Samuelson TW, Sarkisian SR Jr, Lubeck DM, Stiles MC, Duh YJ, Romo EA, Giamporcaro JE, Hornbeak DM, Katz LJ. Prospective, randomized, controlled pivotal trial of an ab interno implanted trabecular micro-bypass in primary open-angle glaucoma and cataract: two-year results. Ophthalmology 2019;126(6):811-821.<br>18 Patel V, Ahmed I, Podbielski D, Falvey H, Murray J, Goeree R. Cost-effectiveness analysis of standalone trabecular micro-bypass stents in patients with mild-to-moderate open-angle glaucoma in Canada. J Med Econ 2019;22(4):390-401.<br>19 Shiroiwa T, Fukuda T, Ikeda S, Takura T, Moriwaki K. Development of an official guideline for the economic evaluation of drugs/medical devices in Japan. Value Health 2017;20(3):372-378.<br>20 Ahmed IIK, Podbielski DW, Patel V, Falvey H, Murray J, Botteman M, Goeree R. A Canadian cost-utility analysis of 2 trabecular microbypass stents at time of cataract surgery in patients with mild to moderate open-angle glaucoma. Ophthalmol Glaucoma 2020;3(2):103-113.<br>21 Mills RP, Budenz DL, Lee PP, Noecker RJ, Walt JG, Siegartel LR, Evans SJ, Doyle JJ. Categorizing the stage of glaucoma from pre-diagnosis to end-stage disease. Am J Ophthalmol 2006;141(1):24-30.<br>22 Ono T, Yuki K, Asaoka R, Kouyama K, Abe T, Tanabe S, Fukagawa K, Uchino M, Shimoyama M, Ozawa Y, Ozeki N, Shiba D, Tsubota K. Glaucomatous visual field defect severity and the prevalence of motor vehicle collisions in Japanese: a hospital/clinic-based cross-sectional study. J Ophthalmol 2015;2015:497067.<br>23 Leske MC, Heijl A, Hussein M, et al. Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Arch Ophthalmol 2003;121(1):48-56.<br>24 Wang JJ, Mitchell P, Simpson JM, Cumming RG, Smith W. Visual impairment, age-related cataract, and mortality. Arch Ophthalmol 2001;119(8):1186-1190.<br>25 van Gestel A, Schouten JSAG, Beckers HJM, Severens JL, Hendrikse F, Webers CAB. The long term effectiveness and cost-effectiveness of initiating treatment for ocular hypertension. Acta Ophthalmol 2014;92(6):513-523.<br>26 Nieland K, Labbé A, Schweitzer C, Gicquel G, Kleintjens J, Ostawal A, Treur M, Falvey H. A cost-effectiveness analysis of iStent inject combined with phacoemulsification cataract surgery in patients with mild-to-moderate open-angle glaucoma in France. PLoS One 2021;16(6):e0252130.<br>27 van Gestel A, Webers CA, Severens JL, Beckers HJ, Jansonius NM, Hendrikse F, Schouten JS. The long-term outcomes of four alternative treatment strategies for primary open-angle glaucoma. Acta Ophthalmol 2012;90(1):20-31.<br>28 Ministry of Health, Labour and Welfare. Various information on medical fees, April 2020. https://shinryohoshu.mhlw.go.jp/shinryohoshu/kaitei/doKaiteiR02;jsessionid=5C49509B945B58423A79A5DAD7640FBB<br>29 Inoue K. Characteristics and segregation of each glaucoma combination ophthalmic drug. Ophthalmology 2018;60(12):1491-1495.<br>30 Ministry of Health, Labour and Welfare. Drug Master Search, April 2021. https://www.mhlw.go.jp/topics/2021/04/tp20210401-01.html<br>31 Ministry of Health, Labour and Welfare. Labor statistics, 2019. https://www.mhlw.go.jp/toukei/itiran/roudou/chingin/kouzou/z2019/dl/01.pdf<br>32 Ministry of Health, Labour and Welfare. Long-term care insurance statistics. Survey of Long-term Care Benefit Expenditures, May 2020.<br>33 Hasegawa M, Komoto S, Shiroiwa T, Fukuda T. Formal implementation of cost-effectiveness evaluations in Japan: a unique health technology assessment system. Value Health 2020;23(1):43-51.<br>34 Teus MA, Belda JI, Lavín C, García-Feijoà J, Falvey H, Buseghin G, Soler M, Appierto M. Cost-effectiveness analysis of iStent inject® implantation during cataract surgery compared to cataract surgery alone for mild to moderate open-angle glaucoma patients in Spain. Expert Review of Ophthalmology 2021:1-10.<br>35 Bartelt-Hofer J, Flessa S. Comparative efficacy and cost-utility of combined cataract and minimally invasive glaucoma surgery in primary open-angle glaucoma. Int Ophthalmol 2020;40(6):1469-1479.
    Related
    Cited by
    Comments
    Comments
    分享到微博
    Submit
Get Citation

Ataru Igarashi, Kyoko Ishida, Nobuyuki Shoji,/et al.iStent inject and cataract surgery for mild-to-moderate primary open angle glaucoma in Japan: a cost-utility analysis. Int J Ophthalmol, 2022,15(6):954-961

Copy
Share
Article Metrics
  • Abstract:656
  • PDF: 883
  • HTML: 0
  • Cited by: 0
Publication History
  • Received:September 22,2021
  • Revised:December 17,2021
  • Online: May 31,2022